AstraZeneca invests $1.5bn in Singapore facility for next-generation cancer drugs
The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be designed to be "zero carbon" from its first day of operation in 2029.
Fransebas
May 21, 2024
British-Swedish pharmaceutical giant AstraZeneca has said it plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates ADCs, to help enhance the global supply of its ADC portfolio, according to a May 20 media release.
ADCs are next-generation treatments that deliver cancer-killing agents directly to cancer cells through a targeted antibody. The manufacturing of ADCs includes antibody production the synthesis of chemotherapy drug and linker the conjugation of drug-linker to the antibody and the filling of the completed ADC substance.
AstraZeneca said that it aims to begin design and construction of the manufacturing facility by the end...
¬ Haymarket Media Limited. All rights reserved.
FinanceAsia has updated its subscription model.
Registered readers now have the opportunity to read 1 article per month from our award-winning website for free.
To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.
To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222
